IS2019B - Nýtt kristallað form kalíumsalts (S)-ómeprasóls - Google Patents

Nýtt kristallað form kalíumsalts (S)-ómeprasóls

Info

Publication number
IS2019B
IS2019B IS5989A IS5989A IS2019B IS 2019 B IS2019 B IS 2019B IS 5989 A IS5989 A IS 5989A IS 5989 A IS5989 A IS 5989A IS 2019 B IS2019 B IS 2019B
Authority
IS
Iceland
Prior art keywords
omeprazole
crystalline form
potassium salt
new crystalline
new
Prior art date
Application number
IS5989A
Other languages
English (en)
Other versions
IS5989A (is
Inventor
Nilsson Maths
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IS5989A publication Critical patent/IS5989A/is
Publication of IS2019B publication Critical patent/IS2019B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
IS5989A 1999-01-28 2001-07-05 Nýtt kristallað form kalíumsalts (S)-ómeprasóls IS2019B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9900274A SE9900274D0 (sv) 1999-01-28 1999-01-28 New compound
PCT/SE2000/000087 WO2000044744A1 (en) 1999-01-28 2000-01-18 Potassium salt of ($i(s))-omeprazole

Publications (2)

Publication Number Publication Date
IS5989A IS5989A (is) 2001-07-05
IS2019B true IS2019B (is) 2005-06-15

Family

ID=20414267

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5989A IS2019B (is) 1999-01-28 2001-07-05 Nýtt kristallað form kalíumsalts (S)-ómeprasóls

Country Status (40)

Country Link
US (1) US6511996B1 (is)
EP (1) EP1149090B1 (is)
JP (1) JP2002535401A (is)
KR (1) KR100624054B1 (is)
CN (1) CN1231477C (is)
AR (1) AR022425A1 (is)
AT (1) ATE236899T1 (is)
AU (1) AU768676B2 (is)
BG (1) BG65060B1 (is)
BR (1) BR0007647A (is)
CA (1) CA2357744C (is)
CZ (1) CZ300504B6 (is)
DE (1) DE60002042T2 (is)
DK (1) DK1149090T3 (is)
DZ (1) DZ3001A1 (is)
EE (1) EE04240B1 (is)
EG (1) EG23980A (is)
ES (1) ES2193937T3 (is)
HK (1) HK1041259B (is)
HU (1) HU226766B1 (is)
ID (1) ID30095A (is)
IL (1) IL144107A0 (is)
IS (1) IS2019B (is)
MY (1) MY119095A (is)
NO (1) NO319719B1 (is)
NZ (1) NZ512804A (is)
PL (1) PL197881B1 (is)
PT (1) PT1149090E (is)
RS (1) RS50200B (is)
RU (1) RU2237666C2 (is)
SA (1) SA00200895B1 (is)
SE (1) SE9900274D0 (is)
SI (1) SI1149090T1 (is)
SK (1) SK285626B6 (is)
TN (1) TNSN00017A1 (is)
TR (1) TR200102138T2 (is)
TW (1) TWI269795B (is)
UA (1) UA71594C2 (is)
WO (1) WO2000044744A1 (is)
ZA (1) ZA200105526B (is)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6875872B1 (en) * 1993-05-28 2005-04-05 Astrazeneca Compounds
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US20070060556A1 (en) * 2003-05-05 2007-03-15 Yatendra Kumar Barium salt of benzimidazole derivative
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
CA2561700A1 (en) * 2004-04-16 2005-12-15 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and prokinetic agent
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
CN103772360A (zh) * 2004-06-24 2014-05-07 阿斯利康(瑞典)有限公司 制备用于制备艾美拉唑钠盐的结晶修饰物的新方法
WO2006073779A1 (en) * 2004-12-30 2006-07-13 Transform Phamaceuticals, Inc. Novel omeprazole forms and related methods
ES2259269B1 (es) 2005-03-03 2007-11-01 Esteve Quimica, S.A. Procedimiento para la preparacion de derivados de 2-(2-piridilmetilsulfinil)-bencimidazol opticamente activos.
US7576219B2 (en) 2005-10-26 2009-08-18 Hanmi Pharm. Co., Ltd Crystalline S-omeprazole strontium hydrate, method for preparing same, and pharmaceutical composition containing same
EP1801110A1 (en) 2005-12-22 2007-06-27 KRKA, tovarna zdravil, d.d., Novo mesto Esomeprazole arginine salt
CN100384839C (zh) * 2006-02-17 2008-04-30 中国科学院上海有机化学研究所 [(取代的吡啶基)甲基]亚磺酰基-1h-苯并咪唑类化合物及其对映体的锌盐的制备方法
US20100286208A1 (en) * 2006-06-21 2010-11-11 Bobba Venkata Siva Kumar Novel polymorph of esomeprazole potassium and process for its preparation
EP2068841B1 (en) 2006-10-05 2018-09-26 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
WO2008057802A2 (en) 2006-10-27 2008-05-15 The Curators Of The University Of Missouri Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same
US7906678B2 (en) 2006-12-04 2011-03-15 Bayer Schering Pharma Aktiengesellschaft Crystalline potassium salt of lipoxin A4 analogs
FR2920428B1 (fr) * 2007-08-29 2012-06-15 Univ Rouen Procede de dedoublement de sels de l'omeprazole
WO2009074997A2 (en) * 2007-12-10 2009-06-18 Lee Pharma Ltd. A novel process for the preparation of crystalline magnesium salt of (s)-omeprazole di hydrate
EP2143722A1 (en) 2008-07-09 2010-01-13 Lek Pharmaceuticals D.D. Process for preparation of esomeprazole sodium of high chemical purity and new forms of esomeprazole sodium
WO2010097583A1 (en) 2009-02-24 2010-09-02 Cipla Limited Esomeprazole potassium polymorph and its preparation
WO2010122583A2 (en) 2009-04-24 2010-10-28 Rubicon Research Private Limited Oral pharmaceutical compositions of acid labile substances
SI2510089T1 (sl) 2009-12-08 2015-12-31 Codexis, Inc. Sinteza prazolnih spojin
CN102319223B (zh) * 2011-09-21 2013-06-19 石药集团欧意药业有限公司 一种埃索美拉唑冻干制剂及其制备方法
CN102633776B (zh) * 2012-03-28 2014-06-18 中山市仁合药业有限公司 一种埃索美拉唑及其钠盐的制备方法
WO2024075017A1 (en) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition of aortic valve calcification

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
SE8301182D0 (sv) 1983-03-04 1983-03-04 Haessle Ab Novel compounds
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
DE4035455A1 (de) 1990-11-08 1992-05-14 Byk Gulden Lomberg Chem Fab Enantiomerentrennung
US5877192A (en) 1993-05-28 1999-03-02 Astra Aktiebolag Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole
SE9301830D0 (sv) 1993-05-28 1993-05-28 Ab Astra New compounds
ATE414509T1 (de) 1994-07-08 2008-12-15 Astrazeneca Ab Aus vielen einzeleinheiten zusammengesetzte tablettierte dosisform
SE504459C2 (sv) 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
GB9423970D0 (en) 1994-11-28 1995-01-11 Astra Ab Oxidation
GB9423968D0 (en) 1994-11-28 1995-01-11 Astra Ab Resolution
HRP960232A2 (en) 1995-07-03 1998-02-28 Astra Ab A process for the optical purification of compounds
SE510666C2 (sv) * 1996-12-20 1999-06-14 Astra Ab Nya Kristallmodifikationer
SE510650C2 (sv) * 1997-05-30 1999-06-14 Astra Ab Ny förening
SE510643C2 (sv) * 1997-06-27 1999-06-14 Astra Ab Termodynamiskt stabil omeprazol natrium form B

Also Published As

Publication number Publication date
UA71594C2 (uk) 2004-12-15
EG23980A (en) 2008-02-27
AU2469400A (en) 2000-08-18
YU53801A (sh) 2004-07-15
BG105841A (en) 2002-04-30
CN1339034A (zh) 2002-03-06
CA2357744A1 (en) 2000-08-03
NO20013665L (no) 2001-07-26
EE200100395A (et) 2002-10-15
DK1149090T3 (da) 2003-06-30
NZ512804A (en) 2003-07-25
CN1231477C (zh) 2005-12-14
TNSN00017A1 (fr) 2005-11-10
SE9900274D0 (sv) 1999-01-28
ATE236899T1 (de) 2003-04-15
AR022425A1 (es) 2002-09-04
EP1149090A1 (en) 2001-10-31
SK10372001A3 (sk) 2002-02-05
RU2237666C2 (ru) 2004-10-10
CZ300504B6 (cs) 2009-06-03
IS5989A (is) 2001-07-05
CA2357744C (en) 2009-06-16
EE04240B1 (et) 2004-02-16
HUP0105313A2 (hu) 2002-05-29
SI1149090T1 (en) 2003-10-31
SK285626B6 (sk) 2007-05-03
BG65060B1 (bg) 2007-01-31
CZ20012730A3 (cs) 2002-02-13
DE60002042T2 (de) 2003-12-18
NO319719B1 (no) 2005-09-05
WO2000044744A1 (en) 2000-08-03
KR100624054B1 (ko) 2006-09-18
RS50200B (sr) 2009-07-15
TWI269795B (en) 2007-01-01
JP2002535401A (ja) 2002-10-22
HK1041259A1 (en) 2002-07-05
PT1149090E (pt) 2003-07-31
HU226766B1 (en) 2009-09-28
ZA200105526B (en) 2002-10-04
KR20010101699A (ko) 2001-11-14
IL144107A0 (en) 2002-05-23
DE60002042D1 (de) 2003-05-15
US6511996B1 (en) 2003-01-28
ID30095A (id) 2001-11-01
SA00200895B1 (ar) 2006-11-11
TR200102138T2 (tr) 2001-12-21
HK1041259B (zh) 2003-10-24
DZ3001A1 (fr) 2004-03-27
AU768676B2 (en) 2003-12-18
PL197881B1 (pl) 2008-05-30
ES2193937T3 (es) 2003-11-16
MY119095A (en) 2005-03-31
HUP0105313A3 (en) 2003-01-28
BR0007647A (pt) 2001-10-16
NO20013665D0 (no) 2001-07-26
EP1149090B1 (en) 2003-04-09

Similar Documents

Publication Publication Date Title
IS2019B (is) Nýtt kristallað form kalíumsalts (S)-ómeprasóls
DK0991641T3 (da) Krystallinsk form af omeprazol-natriumsalt
DE60038481D1 (de) Kristalline form des (r)-2-äää3-methyl-4-(2,2,2-trifluorethoxy)-2-pyridinylümethylüsulfinylü-1h-benzimidazols
EE200300001A (et) Perindopriili tert-butüülamiinsoola kristallilinealfa-vorm
IS5640A (is) Ný kristalla form af Bensímídazól efnasambandi gegn veirum
EE200100135A (et) EtO2C-CH2-(R)Cgl-Aze-Pab-OH kristalsed vormid
NO20020030D0 (no) Krystallinske 1-metylcarbapenemforbindelser
ATE282038T1 (de) Kristallin form ii von cabergolin
ATE339438T1 (de) Substanziell kristalline form von melagatran
IS5821A (is) Kristalluð form af ósanetant
EE200100381A (et) Morfolinobensamiidi uued soolad
EE200100017A (et) N-tert-butüülhüdroksüülamiini uued soolad
PT1175417E (pt) Compostos substituidos de benzolactamas
NO20030416L (no) Krystallinsk terapeutisk forbindelse
ID30381A (id) Penggunaan arilalkanoilpiridazina
DE59907344D1 (de) Feinteiliges kristallines Natriumdisilikat
NO20004583D0 (no) Krystallinsk form av paroxetine
PT1020132E (pt) Aba de puxar destacavel
ATE414059T1 (de) Kristalline form des natriumsalzes von 5-chlor-2- methoxy-n-(2-(4-methoxy-3- methylaminothiocarbonylaminosulfonylphenyl)ethy )bnzamid
SE9904417D0 (sv) Crystalline form
DK1191025T3 (da) Krystaller af lansoprazol
ATE556047T1 (de) Kristalline feste form der (2s-5z)-2-amino-7-
SI0991641T1 (en) Crystalline form of omeprazole sodium salt
SE0001187D0 (sv) Crystalline form